Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 7/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828652 | 1.00 | SMO (0.51) | SMOCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL1830933 | 1.00 | SMO (0.51) | SMOCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL2214332 | 0.87 | CSNK1E (0.47) | SMOCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL2214340 | 0.87 | CSNK1E (0.47) | SMOCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL3225417 | 0.87 | SMO (0.53) | SMOCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL3225407 | 0.87 | SMO (0.53) | SMOCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL12435066 | 0.85 | SMO (0.40) | SMOCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL2275050 | 0.84 | SMO (0.58) | SMOCSNK1EGAAMEN1KMT2A | |
| SCHEMBL2275061 | 0.84 | SMO (0.58) | SMOCSNK1EGAAMEN1KMT2A | |
| SCHEMBL2278195 | 0.84 | SMO (0.58) | SMOCSNK1EGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358703-B1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010056620-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | SMO, SHH, GLI1 | SMO 1/4885CSNK1E 2260/4885MAPK13 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.